Alpha Cognition Inc (ACOG)vsargenx NV ADR (ARGX)
ACOG
Alpha Cognition Inc
$8.90
0.00%
HEALTHCARE · Cap: $193.82M
ARGX
argenx NV ADR
$984.39
+0.04%
HEALTHCARE · Cap: $64.63B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 34731% more annual revenue ($5.32B vs $15.26M). ARGX leads profitability with a 32.3% profit margin vs -137.7%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ACOG
Avoid28
out of 100
Grade: F
ARGX
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACOG.
Margin of Safety
+64.8%
Fair Value
$2371.09
Current Price
$984.39
$1386.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 267.6% year-over-year
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -43.8% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 183.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ACOG
The strongest argument for ACOG centers on Revenue Growth. Revenue growth of 267.6% demonstrates continued momentum.
Bull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bear Case : ACOG
The primary concerns for ACOG are EPS Growth, Market Cap, Return on Equity.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
ACOG profiles as a hypergrowth stock while ARGX is a growth play — different risk/reward profiles.
ACOG carries more volatility with a beta of 2.24 — expect wider price swings.
ACOG is growing revenue faster at 267.6% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 28/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alpha Cognition Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alpha Cognition Inc. is a pioneering biopharmaceutical firm dedicated to revolutionizing the treatment landscape for neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's flagship candidate, ACOG-100, seeks to improve cognitive function and tackle significant unmet needs among the aging demographic. With a robust proprietary neuroscience platform and a deep commitment to rigorous research and development, Alpha Cognition is well-positioned for growth as it advances its clinical pipeline and explores new therapeutic avenues. For institutional investors, the company presents a compelling opportunity to contribute to transformative patient care while capitalizing on the expanding healthcare sector.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?